Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | UGCG | Q16739 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754000 | 0.86 | ADRB2 (0.59) | L3MBTL1ABCB1KMT2AMEN1 | |
| SCHEMBL19043634 | 0.84 | HTR1A (0.56) | ABCB1HRH3 | |
| SCHEMBL8617655 | 0.83 | POLB (0.47) | L3MBTL1IGF1RUGCGKMT2AMEN1 | |
| SCHEMBL14858345 | 0.82 | UGCG (0.52) | ABCB1UGCGHRH3KMT2AMEN1 | |
| SCHEMBL8622719 | 0.80 | POLB (0.44) | L3MBTL1ABCB1IGF1RUGCGKMT2A | |
| SCHEMBL8622720 | 0.80 | POLB (0.44) | L3MBTL1ABCB1IGF1RUGCGKMT2A | |
| Hydrochloric Acid SCHEMBL11273763 | 0.80 | L3MBTL1 (0.46) | L3MBTL1ABCB1IGF1RHRH3KMT2A | |
| SCHEMBL8618788 | 0.79 | POLB (0.46) | ABCB1UGCGKMT2AMEN1 | |
| SCHEMBL465853 | 0.78 | ABCB1 (0.67) | ABCB1 | |
| SCHEMBL16938190 | 0.76 | ABCB1 (0.68) | ABCB1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| EP-1387829-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002090333-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | CBR1, CBR3, CHRM1 | L3MBTL1 3116/4885ABCB1 1236/4885IGF1R 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.